Combining left atrial appendage closure and catheter ablation for atrial fibrillation: 2-year outcomes from a multinational registry

Karen P. Phillips 1*, Aleksandr Romanov 2, Sergey Artemenko 2, Richard J. Folkeringa 3, Tamas Szili-Torok 4, Gaetano Senatore 5, Kenneth M. Stein 6, Omar Razali 7, Nicole Gordon 6, and Lucas V.A. Boersma 8

1Department of Cardiology, GenesisCare, Greenslopes Private Hospital, Suite 212 Ramsay Specialist Centre, Newdegate Street, Greenslopes, Brisbane 4120, Australia; 2Department of Cardiology, E. Meshalkin National Medical Research Center of the Ministry of Health, Novosibirsk, Russian Federation; 3Department of Cardiology, Medical Centre Leeuwarden, Leeuwarden, Netherlands; 4Department of Cardiology, Erasmus MC, Rotterdam, Netherlands; 5Department of Cardiology, Ospedale Civile, Cire, Italy; 6Boston Scientific Corp, St. Paul, USA; 7Department of Cardiology, National Heart Institute, Kuala Lumpur, Malaysia; and 8Department of Cardiology, St. Antonius Hospital, Nieuwegein, Netherlands

Received 9 July 2019; editorial decision 18 September 2019; accepted 3 October 2019; online publish-ahead-of-print 30 October 2019

Aims
Clinical practice guidelines do not recommend discontinuation of long-term oral anticoagulation in patients with a high stroke risk after catheter ablation for atrial fibrillation (AF). Left atrial appendage closure (LAAC) with Watchman has emerged as an alternative to long-term anticoagulation for patients accepting of the procedural risks. We report on the long-term outcomes of combining catheter ablation procedures for AF and LAAC from multicentre registries.

Methods and results
Data were pooled from two prospective, real-world Watchman LAAC registries running in parallel in Europe/Middle-East/Russia (EWOLUTION) and Asia/Australia (WASP) between 2013 and 2015. Of the 1140 patients, 142 subjects at 11 centres underwent a concomitant AF ablation and LAAC procedure. The mean CHA2DS2-VASc score was 3.4 ± 1.4 and HAS-BLED score 1.5 ± 0.9. Successful LAAC was achieved in 99.3% of patients. The 30-day device and/or procedure-related serious adverse event rate was 2.1%. After a mean follow-up time of 726 ± 91 days, 92% of patients remained off oral anticoagulation. The rates of the composite endpoint of ischaemic stroke/transient ischaemic attack/systemic thromboembolism were 1.09 per 100 patient-years (100-PY); and for non-procedural major bleeding were 1.09 per 100-PY. These represent relative reductions of 84% and 70% vs. expected rates per risk scores.

Conclusion
The long-term outcomes from these international, multicentre registries show efficacy for all-cause stroke prevention and a significant reduction in late bleeding events in a population of high stroke risk post-ablation patients who have been withdrawn from oral anticoagulation.

Keywords
Left atrial appendage • Device occlusion • Catheter ablation • Atrial fibrillation • Watchman

Introduction
No randomized controlled trials to date have shown a reduction in the risk of thromboembolic events or ischaemic stroke following catheter ablation therapy for atrial fibrillation (AF) as compared with standard medical therapy and oral anticoagulation. The CHA2DS2-VASc risk score has been shown to correlate with both risk of AF recurrence and risk of thromboembolic events post-ablation, and...
What’s new?

- This study reports on long-term outcomes from a subset of patients who underwent combined catheter ablation for atrial fibrillation and left atrial appendage closure procedures while enrolled in the large real-world WASP and EWOLUTION Watchman Registries.
- The results provide further multicentre evidence that the combined procedure provides efficacious long-term stroke prevention as well as reduced risk of major bleeding by allowing high-risk post-ablation patients to safely stop oral anticoagulation.

underscores the need for on-going stroke protection in high-risk patients. Accordingly, clinical practice guidelines recommend continuation of long-term oral anticoagulation in high stroke risk patients following catheter ablation therapy.3

Catheter-based left atrial appendage (LAA) occlusion, in contrast, has demonstrated efficacy for all-cause stroke prevention in non-valvular AF and can provide a mechanical alternative to long-term anticoagulation. It has been suggested that combining the two left atrial interventions may be a valuable and practical approach.5 We report on the 2-year outcomes of combined catheter ablation procedures for AF with LAA closure as studied in prospective international multicentre registries.

Methods

The study design has previously been described in detail in the first report on peri-procedural outcomes.6 Subgroup analysis was planned prospectively for patients undergoing concomitant catheter ablation of AF with Watchman (Boston Scientific Corporation; Natick, MA, USA) left atrial appendage closure (LAAC) during participation in either the EWOLUTION or WASP registries. The EWOLUTION and WASP registries were designed to collect real-world usage and outcomes data for patients enrolled in the large real-world WASP and EWOLUTION registries. The EWOLUTION and WASP registries were monitored by an outside contract research organization on an ongoing basis with one or more site visits depending on the number of patients enrolled and compliance review.

Both trials required serious adverse events (SAEs) reporting per ISO 14155 and the MEDDEV 2.7/3 12/2010. Adjudication was performed by investigators with oversight by a Medical Safety Group. Events included procedure-related complications (e.g., serious pericardial effusion, device embolization, and procedure-related stroke) and events related to excessive bleeding (e.g., intracranial or gastrointestinal bleeding) scored according to the Bleeding Academic Research Consortium (BARC) criteria. The definition of various safety events and major bleeding align with reporting standards suggested by the consensus document. Safety events were further classified as Watchman procedure-related, device-related or related to prescribed anticoagulation regimen.

Screening for recurrent atrial tachyarrhythmias and follow-up of rhythm outcomes was left to the physician’s discretion. Data were not collected on rhythm outcomes in the central databases and is not reported on as part of these studies.

Endpoints

Efficacy endpoints required reporting of any occurrence of stroke (including ischaemic or haemorrhagic stroke), death, or systemic embolism (SE). The primary endpoints of this study were efficacy of the procedure and device to prevent the combined endpoint of stroke, transient ischaemic attack (TIA), or SE over 2-year follow-up. Secondary endpoints included assessment of procedural success and safety, assessment of bleeding events, and all-cause mortality over 2-year follow-up.

Statistical analysis

Continuous variables are summarized using the mean, standard deviation, range, and categorical variables with counts and percentages. Predicted risk of annual stroke (in the absence of therapy) and bleeding (during anticoagulant therapy) was extrapolated for each individual subject based on CHA2DS2-VASc and HAS-BLED scores using published literature and then the average risk for the study population was used to determine the expected rates for comparison to observed rates and risk reduction.
calculations. Rates of stroke, TIA, SE, death, and bleeding events are calculated as number of events per 100 patient-years (100-PY) and estimates of rates and 95% confidence intervals for each subgroup are derived from a Poisson Model. The Kaplan–Meier method was used to describe SAE rates at specific time points in follow-up. The Fisher’s exact test was used to compare binomial proportions, and t-test to compare continuous variables.

Results

Patient demographics
Enrolment in the EWOLUTION study included 1025 patients and spanned from October 2013 to May 2015 in 47 centres across 13 countries in Europe, the Middle East, and Russia. Enrolment in the WASP trial commenced in January 2014 and concluded in October 2015, resulting in 201 patients across seven countries including Australia, Asia, and the Middle East.

Of the 1140 patients from both registries, 142 subjects at 11 centres underwent a concomitant ablation and LAAC procedure and are included in the analysis. The majority of cases (97%) were performed by experienced AF catheter ablation proceduralists (≥50 procedures per year). The results have previously been published in part as an initial report on 30-day procedural outcomes. Subsequent to the initial publication site monitoring visits revealed three additional patients who had undergone concomitant catheter ablation procedures for AF but had been initially incorrectly classified in the database.

The mean age at time of consent was 64.2 ± 7.2 years (range 39–85), and 54.2% of patients were male. Stroke risk scores (mean ± standard deviation) for CHADS2 and CHA2DS2-VASc were 2.2 ± 1.2 and 3.4 ± 1.4, respectively, while the HAS-BLED score was 1.5 ± 0.9. The primary AF pattern was paroxysmal in 69%. A prior history of ischaemic stroke or TIA was recorded in 40.1% of patients, congestive heart failure in 33.8%, and left ventricular systolic dysfunction [left ventricular ejection fraction (LVEF) <40%] in 2.1%. The indications for LA device occlusion included lable international normalized ratios (INRs) in 25 (17.6%), requirement for concomitant drug therapy in 45 (31.7%), previous major bleeding in 14 (9.9%), recurrent anaemia due to gastrointestinal bleeding in 4 (2.8%), history of blood dyscrasia in 1 (0.7%), history of haemorrhagic tendency in 5 (3.5%), alcohol abuse in 8 (5.6%), senility in 1 (0.7%), job or lifestyle that prohibits warfarin use in 28 (19.7%), other contraindication, e.g. history of ischaemic/haemorrhagic stroke 28.9% (41/142), Prior major bleeding or predisposition to bleeding 4.9% (7/142), history of TIA/Stroke 40.1% (57/142), female 45.8% (65/142), Components of HAS-BLED scores Uncontrolled hypertension 15.5% (22/142), Hypertension 80.3% (114/142), Abnormal renal function 2.1% (3/142), Abnormal liver function 0.7% (1/142), History of ischaemic/haemorrhagic stroke 28.9% (41/142), Prior major bleeding or predisposition to bleeding 4.9% (7/142), Laboratory INRs 17.6% (25/142), Concomitant use of drugs 31.7% (45/142), Alcohol abuse 5.6% (8/142), Age >65 41.5% (59/142), AF pattern Paroxysmal 69.0% (98/142), Persistent 28.9% (41/142), Long-standing persistent 1.4% (2/142).

Procedural characteristics and success
The ablation modality used by the different operators included irrigated radiofrequency ablation in 106 patients, cryoballoon in one patient, non-irrigated phased radiofrequency multielectrode applications in 30 patients and modality not recorded in five patients. Ablation endpoints were not recorded in the registry dataset. Successful LAAC was achieved in 141/142 (99.3%) with one implant abandoned following the ablation phase of the procedure after recognition of a serious pericardial effusion which required pericentesis. All implants achieved a satisfactory seal (residual leak <5 mm) per device release specifications with 137/141 (97.2%) achieving a complete seal and 4/141 (2.8%) accepting a small peri-device leak. The mean LAA diameter was 20.8 ± 2.8 mm (range 14–28), resulting in final median device size of 24 mm.

Oral anticoagulant regimen
Post-procedure, 92.9% of patients were prescribed an oral anticoagulant [54.2% non-vitamin K antagonist oral anticoagulants (NOAC),

| Table 1 | Baseline characteristics |
|---------|--------------------------|
| Characteristics | Summary statistics |
| Age at time of consent (years) | Mean ± SD 64.2 ± 7.2 Range 39.0–85.0 |
| Age >=80 | 0.7% (1/142) |
| Male | 54.2% (77/142) |
| CHADS2 score—continuous | Mean ± SD 2.2 ± 1.2 Range 0.00–5.00 |
| CHA2DS2-VASc score—continuous | Mean ± SD 3.4 ± 1.4 Range 0.00–7.00 |
| HAS-BLED score—continuous | Mean ± SD 1.5 ± 0.9 Range (0.00, 4.00) |

Values presented are % (N/total) or mean ± standard deviation, range (minimum–maximum).

AF, atrial fibrillation; CHF, congestive heart failure; INRs, international normalized ratios; SD, standard deviation; TIA, transient ischaemic attack.
38.7% on warfarin], 5.6% were given anti-platelet (3.5% dual, 2.1% single), and the remainder received no therapy (1.4%).

Peri-procedural safety
The 7-day device and/or procedure-related SAE rate was 1.4% (0.3–4.5%). The 30-day device and/or procedure-related SAE rate was 2.1% (0.6–5.6%). There were two serious pericardial effusions requiring pericardiocentesis (1.4%): one pericardial effusion was identified during the procedure following the ablation phase (therapeutic INR of 2.6 on warfarin) and required percutaneous drainage with uneventful recovery (but caused LAAC implant to be abandoned), while a second pericardial effusion with tamponade occurred on Day 12 post-procedure and was resolved with pericardiocentesis. There were four significant bleeding events within the first 30 days as previously described7 including gastrointestinal bleeding on NOAC Day 1, frank haematuria on warfarin Day 5, secondary bleed from groin (vascular access) on warfarin on Day 13, and traumatic knee haematoma on NOAC on Day 28 post-procedure. The bleeding SAE rate at 30 days was 2.8% (0.9–6.6%). There were no peri-procedural strokes/TIAs, device embolization or deaths.

Transoesophageal echocardiography follow-up
A first follow-up TOE in patients with a successful implant was performed at least 28 days post-procedure in 109/141 (77%) patients. Satisfactory LAA occlusion was noted in 107/109 (98.2%). Two patients had a jet size >5 mm determined to be due to device migration and were continued on OAC for the duration of the study due to unsuccessful LAA closure. Device-related thrombus (DRT) was detected during early follow-up TOE in three patients (2.1%) while still on OAC (Days 38, 45, and 45). There was no history of reduced LVEF or congestive cardiac failure in patients who developed DRT and all patients were identified to have appropriate positioning of the device (without malrotation) and with complete LAA seal. One patient had a history of paroxysmal AF and two patients had persistent AF prior to the index procedure with CHA2DS2-VASc scores ranging between 2 and 3. The rhythm at the time the thrombus was detected was sinus in two and unrecorded in one patient. Sessile thrombus across the atrial facing surface of the device was noted in one and mobile, pedunculated thrombus was attached to the inferior margin of the device in one, with no data available on the third patient. All patients were taking NOACs at the time of diagnosis which were continued until documented thrombus resolution (4 weeks to 4 months timeframe). All DRT patients were then successfully withdrawn from OAC. Device embolization was detected in one patient on Day 43 as part of investigations for difficulty walking. Radiological assessment detected the device at the distal bifurcation of the aorta. The device was retrieved surgically without complications.

Antithrombotic therapy at follow-up
Subsequent to the first follow-up visit 132/141 (94%) of implanted patients were discontinued from or taking no oral anticoagulant. At 2-year follow-up the following rates of therapy were recorded in implanted patients: 8.0% OAC, 81.9% antiplatelet therapy (1.5% dual and 80.4% single), and 10.1% on no therapy (Figure 1).

Table 2  Endpoint event rates

| Events                        | Rate per 100 patients-years | 95% CI  |
|-------------------------------|-----------------------------|---------|
| Death                         | 0.36                        | 0.05–2.53 |
| Ischaemic stroke SAE          | 0.36                        | 0.05–2.54 |
| Ischaemic stroke/TIA/SE SAE   | 1.09                        | 0.35–3.37 |
| Major bleeding SAE            | 1.83                        | 0.76–4.40 |
| Non-procedure or device-related major bleeding SAE | 1.09 | 0.35–3.38 |

SAE, serious adverse event; SE, systemic embolism; TIA, transient ischaemic attack.

Long-term follow-up
The mean follow-up time for the cohort who were successfully implanted was 726 ± 91 days (range 77–902). No patients were lost to follow-up. Two patients underwent cardiac surgery during which the surgeon chose to remove the LAA occlusion device and oversee the LAA in the absence of any documented adverse events related to the device. A total of five patients had bleeding events during 24 months of follow-up with four events clustered within the first 30 days and only one further event (gastrointestinal bleeding from acute diverticulitis while on Aspirin) at Day 199. The observed total major bleeding event rate was 1.83 per 100-PY; however, the non-procedural major bleeding rate was 1.09 per 100-PY. The expected rate of spontaneous major bleeding as predicted by HAS-BLED score if taking warfarin is 3.67 per 100-PY.11 This represents a 70% relative risk reduction for non-procedural bleeding events (Figure 2).

One ischaemic stroke and five TIAs occurred in three patients during follow-up. One patient experienced a TIA Day 15 post-procedure on warfarin and aspirin therapy and was subsequently changed to warfarin and clopidogrel which was then prescribed long-term. This patient was also identified to have device migration resulting in a peri-device leak of 5 mm on follow-up TOE and continued on OAC due to incomplete LAA closure. The same patient went on to suffer an ischaemic stroke on Day 458, and another TIA at day 610 (while still on warfarin and clopidogrel). Two patients experienced three TIAs: one patient at Day 246 on clopidogrel (and was changed to NOAC), a second patient at Day 262 while on warfarin (antiplatelet therapy added), and also on Day 707. The latter patient had a prior history of multiple TIA and strokes, and although had been initially withdrawn from OAC and changed to clopidogrel in early follow-up, he was subsequently recommenced on warfarin by the Neurologist when recurrent AF was detected 11 months post-procedure. There was no evidence for device thrombus in any of the patients who suffered TIA or stroke events. There was no correlation between cases of early detected device thrombus and later stroke/TIA events in the current study. There were no haemorrhagic strokes or intracranial bleeding events.

The expected rate of ischaemic stroke predicted by mean CHA2DS2-VASc score of 3.4 without oral anticoagulation (and assuming aspirin use) is 4.86 per 100-PY.10 However, the observed rate...
for the study was 0.36 per 100-PY (Table 2). This represents a 93% relative risk reduction for stroke. When TIA and SE are added to the combined endpoint the predicted event rate is 6.81 per 100-PY, with an observed rate for the study of 1.09 per 100-PY which translates to 84% relative risk reduction for stroke/TIA/SE (Figure 3).

There was one death over the follow-up period (patient found deceased in bathtub at day 104—cause of death unclear) resulting in a mortality event rate of 0.36 per 100-PY.

**Discussion**

The current study provides long-term registry outcomes for a multinational cohort of patients with AF and high stroke risk who have undergone combined interventions of catheter ablation and LAAC. The study provides important observational data that points to significant lowering of expected stroke event rate despite 92% of patients discontinuing anticoagulation over the longer term. The results also show low rates of bleeding at long-term follow-up, again significantly lower than expected if the patient group had been consistently prescribed anticoagulation. Further the results show good procedural safety for high-volume ablation operators with procedural complication rates similar to those reported for catheter ablation therapy alone. The results are consistent with two other multicentre reports of mid to long-term outcomes following combined ablation and LAAC procedures. A multinational registry which followed up 349 patients with average CHA₂DS₂-VASc score of 3.0 for a mean of 35 months off OAC documented an annualized stroke rate of 0.9% for the cohort (78% risk reduction vs expected) 0.13 A Chinese multicentre registry documented one ischaemic stroke during mean follow-up time of 20 months for a cohort of 50 patients off OAC with mean CHA₂DS₂-VASc score of 3.7. These long-term outcomes further support the acknowledgment that the combined procedure can be described as a ‘valuable and practical approach’ as stated in the 2015 EHRA/EAPCI expert consensus statement on catheter-based LAA occlusion.

The ESC Guidelines for Management of Atrial Fibrillation acknowledge that several observational studies have suggested a relatively low stroke rate in the first few years after catheter ablation of AF, but emphasize that the long-term risk of recurrent AF in ablated patients need to be considered. While the guidelines continue to recommend anticoagulation after ablation based on stroke risk scores rather than rhythm outcome the potential for serious bleeding events in post-ablation patients subjected to long-term anticoagulation has been raised by observational studies such as the Danish National Registry. In the latter study, the incident rates of ischaemic stroke were demonstrated to be higher in the group who discontinued OAC than for those post-ablation patients who remained anticoagulated over the median follow-up time of 3.4 years, but the serious bleeding risks of OAC were suggested to ‘outweigh’ the potential small benefits of stroke risk reduction. While the authors acknowledge that some degree of reduction in stroke risk over the current study timeframe is likely to have been conferred by catheter ablation the concomitant LAAC strategy has provided a proven long-term stroke prevention strategy that is equivalent to oral anticoagulation but with removal of serious bleeding risks and without the ongoing requirement to carefully monitor for recurrent AF.

Global rates of catheter ablation treatment for AF have increased significantly over the last two decades. Despite well-documented improvements in symptoms and quality of life scores catheter ablation has demonstrated few improvements in ‘hard endpoints’ in randomized trials with only the subset of patients with left ventricular systolic dysfunction and congestive cardiac failure showing reductions in mortality. No randomized controlled trial of catheter ablation for AF to date has shown a reduction in long-term thromboembolic events or ischaemic stroke. In contrast, the Watchman LAAC procedure is a catheter-based treatment which has been demonstrated in randomized controlled trials to reduce all-cause stroke and offers improved cardiovascular mortality when compared with warfarin anticoagulation. The combination of LAAC (a proven stroke prevention therapy) with catheter ablation could thereby offer prognostically important outcomes from a single intervention. Further, the prognostic benefit from a ‘bolt-on’ LAAC intervention is likely to be widely applicable due to the prevalence of high stroke risk in the AF population seeking catheter ablation. While the usual decision-making process to arrive at LAAC procedure involves careful
study is notable and is likely explained by 92% of the cohort being

The low rate of long-term (non-procedural) bleeding in the current

Effect on long-term bleeding

The low rate of long-term (non-procedural) bleeding in the current study is notable and is likely explained by 92% of the cohort being discontinued from oral anticoagulation. Long-term therapy with a novel anticoagulant confers an annual major bleeding risk of 2.13–3.6% in contemporary trials. A link between spontaneous bleeding events and a significant increase in mortality has been demonstrated in multiple trials of patients with coronary artery disease. Although the populations are not directly comparable, it may be important to understand the impact of spontaneous major bleeding events on prognosis/mortality in an aging population who are prescribed long-term OAC. PROTECT-AF and the wider meta-analysis of Watchman studies have already demonstrated a clinically and statistically significant reduction in cardiovascular mortality of Watchman LAAC over long-term warfarin anticoagulation and it is intriguing to postulate whether this may be cumulative benefit from reduced major bleeding events in an aging cohort.

Study limitations and future directions

Because these registries were designed as LAAC outcome studies, the datasets did not include arrhythmia outcomes and the authors acknowledge this as a limitation. There is no proof as yet that catheter ablation modifies the risk of thromboembolic stroke in high-risk patients with AF, and long-term follow-up studies following catheter ablation have generally shown progressive arrhythmia recurrence, especially for patients with non-paroxysmal AF. Accordingly, the authors acknowledge that regulatory and reimbursement considerations in different regions around the world will have an impact on the ease with which physicians might adopt the combined approach.

Conclusions

The outcomes from these international, multicentre registries support long-term safety and efficacy of a combined ablation and LAAC procedure for all-cause stroke prevention and a significant reduction
in late bleeding events in a population of high stroke risk post-ablation patients who have been withdrawn from long-term oral anticoagulation.

Funding
This work was supported by the Boston Scientific Inc., St. Paul, USA.

Conflict of interest: Karen Phillips received fees for clinical proctorship/advisory board participation from Boston Scientific, Medtronic and Abbott; Aleksandr Romanov received speaker honoraria from Medtronic, Boston Scientific, Biosense Webster; Kenneth M. Stein and Nicole Gordon are employees of BSC; Omar Razali received speaker’s honoraria from Boston Scientific; Lucas.V.A. Boersma received personal fees from Boston Scientific, Medtronic outside the submitted work.

References
1. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA Randomized Clinical Trial. JAMA 2019;321:1261.
2. Kornej J, Hindricks G, Kosiuk J, Arya A, Sommer P, Husser D et al. Comparison of CHADS2, R2CHADS2, and CHA2DS2-VASc scores for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry. Circ Arrhythm Electrophysiol 2014;7:281–7.
3. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016;18:1609–78.
4. Holmes DR, Doshi SK, Kar S, Price MJ, Sanchez JM, Sievert H et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 2015;65:2614–23.
5. Meier B, Blaauw Y, Khattab A. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. Europace 2015;17:1109–25.
6. Phillips KP, Pokushalov E, Romanov A, Artmenko S, Folkeringa RJ, Szili-Torok T et al. Combining Watchman left atrial appendage closure and catheter ablation for atrial fibrillation: multicentre registry results of feasibility and safety during implant and 30 days follow-up. Europace 2018;20:949–55.
7. Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J 2016;37:2465–74.
8. Phillips KP, Santoso T, Sanders P, Alison J, Chan J, Pak HN et al. Left atrial appendage closure with WATCHMAN in Asian patients: 2-year outcomes from the WASP registry. Int J Cardiol Heart Vasc 2019;23:100358.
9. Tzikas A, Holmes DR Jr, Gafoor S, Ruiz CE, Blomström-Lundqvist C, Diener HC et al. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. Europace 2017;19:4–15.
10. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:1500–10.
11. Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED score. J Am Coll Cardiol 2011;57:173–80.
12. Cappato R, Calcini H, Chen SA, Davies W, Lesaka Y, Kalman J et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3:32–8.
13. Wintgens L, Romanov A, Phillips K, Ballesteros G, Swaans M, Folkeringa R et al. Combined atrial fibrillation ablation and left atrial appendage closure: long-term follow-up from a large multisentre registry. Europace 2018;20:1783–9.
14. Liu FZ, Lin WD, Liao HT, Peng J, Xue YM, Zhan XZ et al. Mid-term outcomes of concomitant left atrial appendage closure and catheter ablation for non-valvular atrial fibrillation: a multicenter registry. Heart Vessels 2019;34:860.
15. Karasyo DS, Gislason GH, Hansen J, Johannessen A, Kober L, Hvidtfeldt M et al. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark. Eur Heart J 2015;36:307–14.
16. Kumar S, Walters TE, Halloran K, Morton JB, Hepworth G, Wong CX et al. Ten-year trends in the use of catheter ablation for treatment of atrial fibrillation vs the use of coronary intervention for the treatment of ischaemic heart disease in Australia. Europace 2013;15:1702–9.
17. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordans L et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417–27.
18. Kumar S, Danik SB, Altman RK, Barrett CD, Lip GY, Chatterjee S et al. Non-vitamin K antagonist oral anticoagulants and antplatelet therapy for stroke prevention in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Cardiol Rev 2016;24:218–23.
19. Hochholzer W, Civitello SD, Antman EM, Contant CF, Guo J, Giugliano RP et al. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 2011;123:2681–9.
20. Ghanbari H, Bajer K, Jangnarangsin K, Chugh A, Nallamothu BK, Gillespie BW et al. Mortality and cerebrovascular events after radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 2014;11:1503–11.